GeneDx Investors Face August Deadline Following Stock Collapse

The lawsuit, Taher Basma v. GeneDx Holdings Corp., filed in the U.S. District Court for the District of Connecticut, alleges that the company and its executives misled shareholders regarding the viability of its $51 million acquisition of Fabric Genomics. While GeneDx initially touted the deal as a way to scale its genomic interpretation services and drive recurring revenue, the complaint claims these statements lacked a reasonable basis and concealed significant operational problems at the acquired firm.

The situation escalated on May 4, 2026, when GeneDx reported a sharp drop in adjusted gross margins and lowered earnings projections. Most notably, the company disclosed a $31.3 million impairment loss tied to Fabric—nearly the entire initial cash outlay for the firm—causing GeneDx shares to plummet by more than 49%. Kessler Topaz Meltzer & Check, LLP is now encouraging affected investors to review their legal options, with a deadline of August 3, 2026, to file for lead plaintiff status in the ongoing litigation.